ArriVentPress Releases Ivesa® Demonstrates Progression Free Survival of Over 20 Months in First-Line Setting for EGFR-Mutated Advanced NSCLC Results from FURLONG study published by The European Lung Cancer Congress Shanghai, China – March…Josh ComolliMarch 31, 2022
ArriVentPress Releases ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors NEWTOWN SQUARE, PA—February 15, 2022—ArriVent…Josh ComolliFebruary 15, 2022
ArriVentPress Releases Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform Aarvik Therapeutics and ArriVent Biopharma Inc. announce a strategic research collaboration to develop and commercialize…Josh ComolliDecember 23, 2021
ArriVentPress Releases ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset Funds will be used to build ArriVent’s portfolio of innovative in-licensed assets for global development…Amy HirschJune 30, 2021